Brian has a B.S. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. BioVentures. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International. She has twenty years of oncology experience with a strong focus on skin cancers, especially malignant melanoma. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women's health). In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. Sadik and his teams have contributed to the successful BLA and MAA applications for three of the commercially available CAR-T therapies: Kymriah, Yescarta, and Tecartus. Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations at RA Capital Management. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Prior RA, Cony was Executive Vice President and Chief Business Officer at Schrdinger for eight years, responsible for business development involving strategic collaborations and new company formation as well as software sales in the US and Japan. Jesse Chen is an EIR at RA Capital. Lauras primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. 239 Kelton St, Allston, MA . Ben Dake is a Venture Associate at RA Capital Management. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division. Adison is an Executive Assistant RA Capital Management. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Kriti holds a B.S. Walter Dauksher is a Junior Associate within the Planetary Health division of RA Capital Management. Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. He works closely with RA's Investment Team on novel drug discovery platforms with emphasis on computational chemistry and machine learning. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . Harvey is a Controller at RA Capital Management. Peter Kolchinsky, Ph.D. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. Largest investment: 7.9 million shares of Vor Biopharma worth $142 million at the time of its IPO . EXCLUSIVE : Robert Morgan's Talaria . Michael held leadership positions at Citigroup Hedge Fund Services in both Fund Accounting and Product Management before joining Centerbridge. Prior to BHP, Brigid was at In-Q-Tel (IQT), the strategic investment arm of the CIA and the US Intelligence Community; she co-founded IQT's Australian subsidiary, served as its Managing Director, and built an international program to support a global innovation initiative through investing in the Asian-Pacific region. Before pursuing an M.B.A. at Harvard Business School, Michael received his M.D. Dan Guglielmo is IT Operations Associate at RA Capital Management. Alyssas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. TipRanks & Hedge Funds: TipRanks measures the performance of Peter Kolchinsky and other hedge fund managers based on information submitted to the SEC. Dan Marks is a Principal on the Venture Team at RA Capital Management. and Ultragenyx Pharmaceuticals. and Novus Biologicals. Alexs primary responsibility at RA Capital is to partner with the Investment Team to develop quantitative analyses to support investment decisions and inform portfolio management. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Monicas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Les primary responsibility is to coordinate various technology related initiatives across the company. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Michael Ryan is an EIR at RA Capital. Chris Caliri is the Chief Information Officer at RA Capital Management. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Phi previously worked as an Executive Assistant at Relay Therapeutics. Cristina holds a Bachelor of Arts in Biochemistry from Mount Holyoke College and a PhD in Cell Biology and Epigenetics from Cornell University and The Rockefeller University. Craig is admitted to practice law in the Commonwealth of Massachusetts. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. Previously, Gunes worked closely with the Investment Team, as a Senior Associate within RAs TechAtlas division. Benjamin previously worked in clinical research as a Site Operations Associate for a contracted research organization specializing in Ophthalmology. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. He conducted his postdoctoral research at Brigham and Womens Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Steve's survey is fascinating. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Prior to RA, Megan worked as a Gastroenterology Fellow at University of Pittsburgh Medical Center and a Resident Physician, Internal Medicine, at Beth Israel Deaconess Medical Center. EMEA +44 20 7330 7500. April 28, 2023 9:39am. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Meredith is a Senior Research Assistant at RA Capital Management. 1 reply 0 retweets 13 likes Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Her contributions involve engagement with teams across RA Capital, including the processing of CDA's. Sonias primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneurs Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression.